Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow Print PDF (359K) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Vilain, N.
Right arrow Articles by Leroy, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vilain, N.
Right arrow Articles by Leroy, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 2003, Vol. 31, No. 19 5714-5722
© 2003 Oxford University Press

Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase II{alpha}

Nathalie Vilain, Monika Tsai-Pflugfelder1,2, Audrey Benoit2,3, Susan M. Gasser1,2 and Didier Leroy*,2,3

Swiss Institute for Experimental Cancer Research, Ch. des Boveresses 155, CH-1066 Epalinges s/Lausanne, Switzerland, 1 Department of Molecular Biology and 2 NCCR Frontiers in Genetics, University of Geneva, Quai Ernest-Ansermet 30, CH-1211 Geneva, Switzerland and 3 Proteomics Platform, Geneva, Switzerland

*To whom correspondence should be addressed at NCCR Frontiers in Genetics, University of Geneva, Quai Ernest-Ansermet 30, CH-1211 Geneva, Switzerland. Tel: +41 22 379 65 90; Fax: +41 22 379 68 68; Email: didier.leroy{at}frontiers-in-genetics.org

Epipodophyllotoxins are effective antitumour drugs that trap eukaryotic DNA topoisomerase II in a covalent complex with DNA. Based on DNA cleavage assays, the mode of interaction of these drugs was proposed to involve amino acid residues of the catalytic site. An in vitro binding study, however, revealed two potential binding sites for etoposide within human DNA topoisomerase II{alpha} (htopoII{alpha}), one in the catalytic core of the enzyme and one in the ATP-binding N-terminal domain. Here we have tested how N-terminal mutations that reduce the affinity of the site for etoposide or ATP affect the sensitivity of yeast cells to etoposide. Surprisingly, when introduced into full-length enzymes, mutations that lower the drug binding capacity of the N-terminal domain in vitro render yeast more sensitive to epipodophyllotoxins. Consistently, when the htopoII{alpha} N-terminal domain alone is overexpressed in the presence of yeast topoII, cells become more resistant to etoposide. Point mutations that weaken etoposide binding eliminate this resistance phenotype. We argue that the N-terminal ATP-binding pocket competes with the active site of the holoenzyme for binding etoposide both in cis and in trans with different outcomes, suggesting that each topoisomerase II monomer has two non-equivalent drug-binding sites.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
Y. Qin, L. Meng, C. Hu, W. Duan, Z. Zuo, L. Lin, X. Zhang, and J. Ding
Gambogic acid inhibits the catalytic activity of human topoisomerase II{alpha} by binding to its ATPase domain
Mol. Cancer Ther., September 1, 2007; 6(9): 2429 - 2440.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
M. Duca, D. Guianvarc'h, K. Oussedik, L. Halby, A. Garbesi, D. Dauzonne, C. Monneret, N. Osheroff, C. Giovannangeli, and P. B. Arimondo
Molecular basis of the targeting of topoisomerase II-mediated DNA cleavage by VP16 derivatives conjugated to triplex-forming oligonucleotides.
Nucleic Acids Res., January 1, 2006; 34(6): 1900 - 1911.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.